Orthofix Medical (Orthofix Medical) COGS-to-Revenue

: 0.32 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

Orthofix Medical's Cost of Goods Sold for the three months ended in Dec. 2023 was $63.8 Mil. Its Revenue for the three months ended in Dec. 2023 was $200.4 Mil.

Orthofix Medical's COGS to Revenue for the three months ended in Dec. 2023 was 0.32.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Orthofix Medical's Gross Margin % for the three months ended in Dec. 2023 was 68.17%.

Orthofix Medical COGS-to-Revenue Historical Data

The historical data trend for Orthofix Medical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthofix Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.22

0.25

0.27

0.35

Orthofix Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.27	0.37	0.36	0.35	0.32

Orthofix Medical COGS-to-Revenue Calculation

Orthofix Medical's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	260.368	/	746.641
	=	0.35

Orthofix Medical's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	63.785	/	200.415
	=	0.32

Orthofix Medical (NAS:OFIX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Orthofix Medical's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	63.785 / 200.415
	=	68.17 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Orthofix Medical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Orthofix Medical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Orthofix Medical (Orthofix Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Orthofix Medical Inc (NAS:OFIX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

OM2:Germany

Address

3451 Plano Parkway, Lewisville, TX, USA, 75056

Website

https://www.orthofix.com

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Executives

James F. Hinrichs	director	3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Puja Leekha	officer: CECO & Interim CLO	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Geoffrey C Gillespie	officer: VP, Controller, Interim CFO	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kevin J. Kenny	officer: President of Global Spine	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Shweta Maniar	director	C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Stuart Essig	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John J. Bostjancic	officer: CFO	C/O SEASPINE HOLDINGS CORPORATION, 2302 LA MIRADA DRIVE, VISTA CA 92081
Keith Valentine	director, officer: President & CEO	7475 LUSK BLVD., SAN DIEGO CA 92121
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Patrick L Keran	officer: Chief Legal Officer	6725 MESA RIDGE RD., SUITE 100, SAN DIEGO CA 92121
Thomas A. West	director	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael E Paolucci	director	7475 LUSK BLVD., SAN DIEGO CA 92121
Catherine M Burzik	director
Rice Doug	officer: CFO	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kimberley A. Elting	officer: Chief Legal Officer	3451 PLANO PARKWAY, LEWISVILLE TX 75056